搜尋
Repligen Corp
RGEN添加自選
136.907USD
-0.093-0.07%
交易中 （美東）報價延遲15分鐘
7.71B總市值
149.88本益比TTM
關鍵數據
137.770今開
138.850最高
311.39K成交量
149.88本益比TTM
52.44本益比動
--股利TTM
0.55%換手率
137.000昨收
134.010最低
32.74M成交額
虧損本益比靜
3.66市淨率
0.00%股息率 TTM
1.78%ROA
175.77052週最高
0.51量比
-25.51M淨利潤
56.33M總股本
0.9135每股盈餘TTM
1.09Beta
2.51%ROE
100.99052週最低
3.53%振幅
55.74%毛利率
7.71B總市值
3.82回報/風險
2.75%風險率
TradingKey Repligen Corp股票評分
單位: USD 更新時間: 2026-06-29操作建議
Repligen Corp當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在醫療設備與耗材行業排名28/204位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為177.75。中期看，股價處於上升通道。近一個月，市場表現較強，技術面和基本面綜合得分較高，較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Repligen Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Repligen Corp亮點
亮點風險
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
業績高增長
公司營業收入穩步增長，連續3年增長16.75%
利潤高增長
公司淨利潤處於行業前列，最新年度總收入738.26M美元
業績轉盈
公司業績轉盈，最新年度盈利美元
估值高估
公司最新PE估值149.98，處於3年歷史高位
機構減倉
最新機構持股65.93M股，環比減少3.85%
李安斯利持倉
明星投資者李安斯利持倉，最新持倉1.58M股
分析師目標
基於
22
分析師
買入
評級
177.749
目標均價
+20.91%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Repligen Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Repligen Corp簡介
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
公司代碼RGEN
公司Repligen Corp
CEOLoeillot (Olivier)
網址https://www.repligen.com/
相關品種
-0.89%
-1.23%
-1.09%
-1.12%
-1.27%
-0.10%
-5.10%
-2.13%
-1.14%
-0.22%
-0.66%
-2.46%
-0.14%
-0.88%
+1.37%
-2.57%
-2.38%
-0.70%
-1.76%
-0.24%熱門品種
52370.700
+217.500 (+0.42%)
30231.100
+523.400 (+1.76%)
7493.800
+61.600 (+0.83%)
15606.000
+155.000 (+1.00%)
71114.000
+640.000 (+0.91%)
6329.900
+74.100 (+1.19%)
69.941
-0.375 (-0.53%)
289.072
+7.332 (+2.60%)
198.020
+3.050 (+1.56%)
4029.830
+14.240 (+0.35%)
常見問題
Repligen Corp(RGEN)的當前股價是多少？
Repligen Corp(RGEN)的當前股價是 137.00。
Repligen Corp 的股票代碼是什麼？
Repligen Corp的股票代碼是RGEN。
Repligen Corp股票的52週最高點是多少？
Repligen Corp股票的52週最高點是175.77。
Repligen Corp股票的52週最低點是多少？
Repligen Corp股票的52週最低點是100.99。
Repligen Corp的市值是多少？
Repligen Corp的市值是7.73B。
現在Repligen Corp(RGEN)的股票是買入、持有還是賣出？
根據分析師評級，Repligen Corp(RGEN)的總體評級為買入，目標價格為177.75。
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是多少
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是0.87。
